本帖最后由 maicon08 于 2023-4-28 15:12 编辑
8 g, V( {& a; ~9 L1 x1 P: U
' O/ C6 N) Q: j( W( r6 i/ R6 v# C一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国大陆研究Oral Abstract Session入选16项，另外Clinical Science Symposium和Rapid Abstract Session部分各有1项中国研究入选，共18项。- o5 J: a G' X" R) Q
5 A) t( X( N, t+ v
https://www.163.com/dy/article/I3BTTPRD053438SI.html8 R4 h# q1 w! X0 q6 q
4 P7 q* A: `" p' q l+ C9 n8 N. c
% i* a# W) r7 }7 d I/ |6 W6 L, ~
在研疗法-免疫治疗
% c( K7 ~: s4 |. }Developmental Therapeutics—Immunotherapy6 V5 j: h$ z' p6 }
4 y. H! ?' ]9 @4 S摘要号：2507 标题：Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors. 报告人：丰恺超 单位：JFJ总医院第一医学中心 . R+ ^# D, C u# Q
在研疗法-分子靶向药物和肿瘤生物学
3 ^9 W$ V' I8 i Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
: r+ O. j# l- ]) K' F摘要号：3001 标题：BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 报告人：张力 单位：中山大学肿瘤防治中心
: Q9 o1 [# I8 h( w- S2 P+ s
摘要号：3007 标题：A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. 报告人：周清 单位：广东省人民医院 ( [! e* I: \" n6 a" P) _: X
胃肠道肿瘤-结直肠癌和肛门癌' B* p4 t+ |/ j/ W
Gastrointestinal Cancer—Colorectal and Anal 摘要号：3505 标题：Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial. 报告人：张剑威 单位：中山大学附属第六医院 + Z3 {: N; G/ `$ x( @
胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
4 }; b* n" [& [' S! M. l摘要号：4001 标题：Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. 报告人：袁庶强 单位：中山大学肿瘤防治中心 ) p9 y& Z {/ g& ?
妇科肿瘤 Gynecologic Cancer
& x5 q' B2 b; w摘要号：5516 标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial. 报告人：田文娟 单位：复旦大学附属肿瘤医院 5 P4 p* j& u1 {( ?# Z/ z
头颈肿瘤
0 O# e3 N9 Z/ v4 X Q6 [ Head and Neck Cancer / ]0 N; M7 }& T5 d0 b2 L0 I
摘要号：6000 标题：Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. 报告人：唐林泉 单位：中山大学肿瘤防治中心
9 H) r5 i, O2 W5 Q1 K
摘要号：6001 标题：Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial. 报告人：陈明远 单位：中山大学肿瘤防治中心 6 F L. j$ T/ _( \
摘要号：LBA6002 标题：PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM). 报告人：马骏 单位：中山大学肿瘤防治中心
0 d/ w Q9 I1 [" V1 \+ s
血液系统恶性肿瘤-淋巴瘤和慢性淋巴细胞白血病 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
" z+ a- z! R8 Z. A& z# l/ z摘要号：7503 标题：Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8). 报告人：蔡清清 单位：中山大学肿瘤防治中心 ; d# y; F; o, d$ \8 a
血液系统恶性肿瘤-浆细胞疾病
, Q# U7 T- P" l Hematologic Malignancies—Plasma Cell Dyscrasia
1 r" t! d7 G' I4 c" C/ ?# H' z3 L摘要号：8005 标题：Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). 报告人：杜鹃 单位：上海长征医院
4 y* \" {2 ?# H
肺癌-非小细胞局部-区域性/小细胞/其他胸部肿瘤
9 \8 q. L0 W, N& a" t$ H Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
1 I3 |3 z8 X* r7 m* o+ R摘要号：8501 标题：Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. 报告人：陆舜 单位：上海交通大学医学院附属胸科医院
8 R* J/ J( s3 }: E
肺癌-转移性非小细胞肺癌
( _- P/ E) h T9 L) s; v Lung Cancer—Non-Small Cell Metastatic
5 a* V! ~! v- y, J6 F0 q$ l摘要号：9001 标题：Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. 报告人：吴一龙 单位：广东省人民医院
* E, x. F* G3 h: l% X1 g& \
9 s" a7 R* O$ B" `* g' U3 g摘要号：9002 标题：Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results. 报告人：王孟昭 单位：北京协和医院 6 v6 L: q3 H0 y
摘要号：9003 标题：Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations. 报告人：邬麟 单位：湖南省肿瘤医院
* r+ g$ _$ q5 H8 E# s
黑色素瘤/皮肤癌
% i& j$ v9 L- I/ Q3 a/ } Melanoma/Skin Cancers 摘要号：9508 标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma. 报告人：郭军 单位：北京大学肿瘤医院 : E" T1 p1 f$ X; M3 U T O R8 d
快速摘要报告* c7 D W/ W0 k H6 w
Rapid Abstract Session 摘要号：LBA1013 标题：TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). 报告人：江泽飞 单位：JFJ总医院第五医学中心 - Y* V1 }; V- r# z- ?% A! k) G# K5 d
临床科学研讨会
- P: x/ z# [- W, m* I# H Clinical Science Symposium 摘要号：11510 标题：The clinical value of tumor-informed minimal residual disease detection in sarcoma. 报告人：尹军强 单位：中山大学附属第一医院
& Y* q2 [7 U* H# b: }/ p3 W& B5 H% v) O- g, V& r4 L) I
| 
发表于 2023-4-28 14:46:30
楼主
发表于 2023-4-28 14:53:34
发表于 2023-4-28 20:42:18
，中肿在保持鼻咽癌和食道癌这些优势的同时，头颈癌和血癌也逐渐发力了
